“We see the goal as supporting higher valuation, when coupled with additional M&A and greater cash generation,” Keywood said. “WELL’s stock has seen some recent pressure with a broader market reset in health-tech but continued profitable growth is unique and the share price should follow higher.”
Overall, WELL Health’s stock price is down 19.8 per cent for the year to date, hitting a high point of $9.23/share on February 24 before going back up and then down again, though it has since bottomed out at $6.30/share.
Disclosure: Nick Waddell and Jayson MacLean own shares in WELL Health Technologies and WELL is an annual sponsor of Cantech Letter.
About The Author /
Geordie Carragher is a staff writer for Cantech Letter